NYU BIOMARKER CLINICAL AND EPIDEMIOLOGIC CENTER FOR CANCER

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 肺癌是美国癌症死亡的主要原因。纽约大学临床和流行病学癌症早期检测中心的总体目标是发展和前瞻性地跟踪具有不同环境癌症风险的前工会成员和活跃工会成员的大量地理分散人口，识别癌前细胞变化和损害，并发现早期癌症。纽约大学的人口将由许多有吸烟史和/或工作场所暴露史的人组成。他们将来自建筑工会，在那里，过去接触石棉的工人在公用事业工人、石棉绝缘体、锅炉制造商、金属板工人、木匠和管道安装工人中很常见。纽约大学中心将有一个分包合同，以筛选与德克萨斯州的一个核武器设施有关的现役和前工人。纽约大学临床和流行病学中心将促进对一大批高危蓝领工作者的招募和抽样，对p53和K-ras基因DNA加合物的分析、对周期周期蛋白依赖的激酶的放松调控、对信号和Rb通路的放松调控以及对癌基因和肿瘤抑制基因的其他生物检测将在最早和最可治疗的阶段检测癌前疾病或癌症。将对某些高危个体进行荧光支气管镜检查，以进行支气管刷和粘膜活检，以评估细胞周期紊乱。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Lung cancer is the leading cause of cancer death in the US. The overall goal of the NYU Clinical and Epidemiologic Center for the Early Detection of Cancer is to develop and prospectively follow large, geographically dispersed populations of former and active union members of varying environmental cancer risk, to identify preneoplastic cellular changes and lesions, and to detect early cancers. The NYU population will consist of many individuals with a history of smoking and/or workplace exposures. They will be drawn from the building trade unions, where past exposure to asbestos was common among utility workers, asbestos insulators, boilermakers, sheet-metal workers, carpenters, and pipefitters. The NYU Center will have a subcontract to screen active and former workers associated with a nuclear weapons facility in Texas. The NYU Clinical and Epidemiologic Center will facilitate recruitment and sampling of a large cohort of high-risk, blue- collarn workers and that assays for DNA-adducts on p53 and K-ras genes, deregulation of the cyclin-cyclin dependent kinases, deregulation of signaling and Rb pathways, and other bioassays for oncogenes and tumor suppressor genes will detect preneoplastic conditions or cancer in the earliest and most treatable stages. Fluorescence bronchoscopy will be performed on certain high risk individuals for bronchial brush and mucosal biopsies to evaluate cell-cycle deregulation.